U.S. markets open in 8 hours 13 minutes
  • S&P Futures

    4,370.25
    -33.50 (-0.76%)
     
  • Dow Futures

    34,033.00
    -220.00 (-0.64%)
     
  • Nasdaq Futures

    14,351.00
    -150.00 (-1.03%)
     
  • Russell 2000 Futures

    2,009.00
    -22.70 (-1.12%)
     
  • Crude Oil

    83.69
    +0.38 (+0.46%)
     
  • Gold

    1,841.90
    +0.20 (+0.01%)
     
  • Silver

    23.84
    +0.04 (+0.17%)
     
  • EUR/USD

    1.1320
    -0.0010 (-0.09%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • Vix

    29.90
    +1.05 (+3.64%)
     
  • GBP/USD

    1.3477
    -0.0014 (-0.10%)
     
  • USD/JPY

    113.7660
    -0.1940 (-0.17%)
     
  • BTC-USD

    36,132.13
    +472.06 (+1.32%)
     
  • CMC Crypto 200

    823.29
    +12.69 (+1.57%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,060.77
    -527.60 (-1.91%)
     

CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • CBAY

NEWARK, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 11, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2020 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 855-327-6837 from the U.S. and Canada, or 631-891-4304 internationally, Conference ID# 10009543. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.

For additional information about CymaBay visit www.cymabay.com.

Contact:
Sloane & Company
Dan Zacchei / Joe Germani, 212-486-9500
Dzacchei@sloanepr.com / JGermani@sloanepr.com